THOUSAND OAKS, Calif.,
Sept. 14, 2016 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced that the Company
will host a webcast call for the investment community on
Monday, Sept. 19, 2016, at
8:30 a.m. PT. Sean E. Harper, M.D., executive vice president
of Research and Development at Amgen, along with members of Amgen's
clinical development team and clinical investigators, will
participate in the call to discuss results from the romosozumab
phase 3 postmenopausal osteoporosis study (FRAME) presented at the
American Society for Bone and Mineral Research Annual Meeting, and
from the erenumab (AMG 334) Phase 2 chronic migraine study
presented at the European Headache and Migraine Trust International
Congress.
Live audio of the investor call will be simultaneously broadcast
over the Internet and will be available to members of the news
media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Kristen Neese, 805-313-8267
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-300328123.html
SOURCE Amgen